AOD9604

AOD9604 is a modified fragment of human growth hormone spanning amino acids 176-191 — the region of the HGH molecule researchers identified as responsible for its fat-metabolizing effect, isolated from the regions responsible for HGH's effects on growth and blood glucose.

Watch

▶ Doctor Explains 20 Most Powerful Peptides

Mechanism

• Lipolysis signaling. Studied for stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation) in adipocyte research models, mirroring the C-terminal fragment's activity within the full HGH molecule.
• Isolated from GH's other effects. Because it excludes HGH's N-terminal region, research indicates it does not significantly affect IGF-1 levels or blood glucose the way full-length HGH does.

Common research protocols

Dosing information below reflects published research literature. It is not medical advice and is not a treatment plan.

• Route. Subcutaneous injection.
• Research context. Subcutaneous dosing is standard in peptide research protocols examining regional fat metabolism.

Evidence at a glance

• Regulatory status. Not FDA-approved. Was studied in human clinical trials for obesity in the 2000s; development did not proceed to approval.
• What we do not know. Efficacy data beyond early-phase trials; optimal research dosing for metabolic endpoints.

Reconstitution & handling

Lyophilized peptides ship as freeze-dried powder. Reconstitute with bacteriostatic water; refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How We Work page.

Primary-literature list for this guide available on request via contact.